Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer

Chung Wei Fan, Chung Chuan Chan, Kuei Tien Chen, Jen Twu, Ya Shu Huang, Chia Li Han, Yu Ju Chen, Jau Song Yu, Yu Sun Chang, Yung Bin Kuo, Err Cheng Chan

研究成果: 雜誌貢獻文章同行評審

13 引文 斯高帕斯(Scopus)


Background: To identify novel serological biomarkers for human colorectal cancer (CRC), we analyzed CRC tissues using gel-assisted digestion and isobaric tags with related and absolute quantitation (iTRAQ) labeling mass spectrometry (MS). By comparing pairs of tumor tissues and matched normal tissues, we discovered the SEC61β with expression changes 3.3-fold and a marginal statistical significance (p= 0.052) previously. Methods: SEC61β expression in CRC tissues was further analyzed by western blotting and immunohistochemistry. We next assessed the putative diagnostic value of the SEC61β autoantibody as a serum marker. Results: Using western blotting analysis, SEC61β expression was increased 1.9-fold in tumor tissues. Immunohistochemical analysis of 64 CRC specimens showed that SEC61β was positively detected in 64% of the tumors, but weakly or not detected in > 80% of the adjacent nontumor epithelial cells. Western blot analysis with plasma samples showed that the sensitivity and specificity of the SEC61β autoantibody from patients with CRC were 79% and 75%, respectively. Importantly, the results of the SEC61β autoantibody for early detection of colorectal cancer revealed a higher sensitivity of 77% than the carcinoembryonic antigen (CEA) assay. Conclusions: Measurement of SEC61β autoantibody levels may provide an alternative detection indicator for CRC, particularly among early-stage patients.

頁(從 - 到)887-893
期刊Clinica Chimica Acta
出版狀態已發佈 - 5月 12 2011

ASJC Scopus subject areas

  • 生物化學
  • 臨床生物化學
  • 生物化學(醫學)


深入研究「Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer」主題。共同形成了獨特的指紋。